BamSEC and AlphaSense Join Forces
Learn More

Achieve Life Sciences Inc.

NASDAQ: ACHV    
Share price (12/20/24): $3.69    
Market cap (12/20/24): $127 million
Search in Documents
Key Exhibits
External Links

Underwriting Agreements Filter

EX-1.1
from 8-K 39 pages Open Market Sale Agreementsm
12/34/56
EX-1.2
from S-3 42 pages Achieve Life Sciences, Inc. Common Stock (Par Value $0.001 Per Share) Atm Sales Agreement
12/34/56
EX-1.1
from 8-K 36 pages 2,857,143 Shares Achieve Life Sciences, Inc. Common Stock Underwriting Agreement
12/34/56
EX-1
from SC 13G/A 1 page Joint Filing Statement Statement Pursuant to Rule 13d-1
12/34/56
EX-1
from SC 13G/A 1 page Exhibit 1 Joint Acquisition Statement Pursuant to Rule 13d-1
12/34/56
EX-1
from SC 13G 1 page Exhibit 1 Joint Acquisition Statement Pursuant to Rule 13d-1
12/34/56
EX-1.1
from S-1/A 56 pages [ ] Shares of Common Stock of Achieve Life Sciences, Inc. Underwriting Agreement
12/34/56
EX-1.1
from 8-K 36 pages Achieve Life Sciences, Inc. Underwriting Agreement
12/34/56
EX-1
from SC 13G 2 pages Joint Filing Statement Statement Pursuant to Rule 13d-1
12/34/56
EX-1.1
from 8-K 86 pages 9,577,504 Shares of Common Stock, 6,256 Shares of Series B Convertible Preferred Stock (Convertible Into 10,422,496 Shares of Common Stock), and 20,000,000 Warrants (Exercisable for 20,000,000 Shares of Common Stock) of Achieve Life Sciences, Inc. Underwriting Agreement
12/34/56
EX-1.1
from S-1/A 88 pages [ ] Shares of Common Stock, [ ] Shares of Series B Convertible Preferred Stock (Convertible Into [ ] Shares of Common Stock), and [ ] Warrants (Exercisable for [ ] Shares of Common Stock) of Achieve Life Sciences, Inc. Underwriting Agreement
12/34/56
EX-1.1
from S-1/A 86 pages [ ] Shares of Common Stock, [ ] Shares of Series B Convertible Preferred Stock (Convertible Into [ ] Shares of Common Stock), and [ ] Warrants (Exercisable for [ ] Shares of Common Stock) of Achieve Life Sciences, Inc. Underwriting Agreement
12/34/56
EX-1.1
from 8-K 40 pages At the Market Offering Agreement June 7, 2019
12/34/56
EX-1
from SC 13G 1 page Joint Filing Agreement
12/34/56
EX-1.1
from 8-K 14 pages Placement Agency Agreement October 1, 2018
12/34/56
EX-1.1
from 8-K 87 pages 710,500 Shares of Common Stock, 9,158 Shares of Series a Convertible Preferred Stock (Convertible Into 2,289,500 Shares of Common Stock), and 3,000,000 Warrants (Exercisable for 3,000,000 Shares of Common Stock) of Achieve Life Sciences, Inc. Underwriting Agreement
12/34/56
EX-1
from S-1/A 82 pages Shares of Common Stock, Shares of Series a Convertible Preferred Stock (Convertible Into Shares of Common Stock), and Warrants (Exercisable for Shares of Common Stock) of Achieve Life Sciences, Inc. Underwriting Agreement
12/34/56
EX-1.1
from 8-K 9 pages April 28, 2015 Mr. Scott D. Cormack President and Chief Executive Officer Oncogenex Pharmaceuticals, Inc. 19820 North Creek Parkway, Suite 201 Bothell, Wa 98021 Re: Engagement of Academy Securities, Inc. as Placement Agent for Oncogenex Pharmaceuticals, Inc. Ladies and Gentlemen
12/34/56
EX-1.1
from 8-K 72 pages Oncogenex Pharmaceuticals, Inc. 5,559,866 Shares Pre-Funded Warrants to Purchase 1,340,538 Shares Warrants to Purchase 3,450,202 Shares Common Stock ($0.001 Par Value) Underwriting Agreement
12/34/56
EX-1.1
from 8-K 46 pages Oncogenex Pharmaceuticals, Inc. Common Stock (Par Value $0.001 Per Share) At-The-Market Issuance Sales Agreement
12/34/56